Japan's Takeda on the hunt for new drugs to support growth
Singapore
AFFORDABILITY of drugs is the single biggest challenge for not just governments looking to keep a lid on healthcare costs, but also for drug makers hunting for growth and pressured to find new treatments to cope with the rapid rise in patients' need for medicines.
The Asia-Pacific region alone bears 25 per cent of the global disease burden, and the problem is amplified by a fast-ageing population and rise in lifestyle-induced diseases in places including Korea and Taiwan, says Gordon Cameron, area vice-president, Asia-Pacific, at Takeda Pharmaceuticals.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Binance and CZ’s fortunes are set to grow, jail or no jail
Stocks to watch: Wilmar, MLT, FEHT, CDLHT, Starhill Global Reit, IReit Global
Samsung says Q1 operating profits soar nearly tenfold on-year
Far East Hospitality Trust Q1 net property income rises 6% to S$25.1 million
Boeing gets a welcome respite with US$10 billion bond offering
Hong Kong vies with US in Bitcoin ETF market after crypto’s revival